tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT

Inhibikase Therapeutics (IKT) Revenue

Compare
172 Followers

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had a revenue of 0.00 in the quarter ending Sep 30, 2025, with ―. This bring the company's revenue in the last twelve months to 0.00, Decreased ―. In the fiscal year ending Dec 31, 2024, Inhibikase Therapeutics had annual revenue of 0.00 with -100.00% growth.
Revenue (ttm)
0.00
Revenue Growth
-100.00%
P/S Ratio
Revenue/Employee
$0
Employees
15
Market Cap
$200.09M

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
-260.50K
Dec 31, 2023
260.50K137.06K+211.04%
Dec 31, 2022
123.44K-2.98M+3.98%
Dec 31, 2021
3.10M2.40M+443.92%
Dec 31, 2020
698.47K-424.27K+62.21%
Dec 31, 2019
1.12M-2.92M+27.78%
Dec 31, 2018
4.04M1.98M+196.07%
Dec 31, 2017
2.06M1.09M+213.04%
Dec 31, 2016
967.39K